154 related articles for article (PubMed ID: 19892524)
21. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol.
Murthy BP; Skee DM; Danyluk AP; Brett V; Vorsanger GJ; Moskovitz BL
Curr Med Res Opin; 2007 Feb; 23(2):275-84. PubMed ID: 17288681
[TBL] [Abstract][Full Text] [Related]
23. [A single daily dose with valproic acid. A pharmacodynamic and clinical study].
Pelzl G; Mamoli B
Wien Klin Wochenschr; 1992; 104(10):286-9. PubMed ID: 1604872
[TBL] [Abstract][Full Text] [Related]
24. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
Reed RC; Dutta S
Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
[TBL] [Abstract][Full Text] [Related]
25. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate.
Rinnerthaler M; Luef G; Mueller J; Seppi K; Wissel J; Trinka E; Bauer G; Poewe W
Epilepsia; 2005 Feb; 46(2):320-3. PubMed ID: 15679514
[TBL] [Abstract][Full Text] [Related]
26. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?
Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC
J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651
[TBL] [Abstract][Full Text] [Related]
27. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
Pierre-Louis SJ; Brannegan RT; Evans AT
Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
[TBL] [Abstract][Full Text] [Related]
28. [Valproate sustained release in the treatment of epilepsy].
Stefan H; Fraunberger B
Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
[TBL] [Abstract][Full Text] [Related]
29. Chrono impact versus enteric coated valproate in Thai epileptic patients.
Towanabut S; Tiemkao S; Thammasupapong S; Kijjarak R; Arayawichanon A; Poungvarin N; Sirimaharaj S; Chaisewikul R; Asawavichenjinda T; Maneesuk S; Silpakit O
J Med Assoc Thai; 2005 Nov; 88(11):1651-9. PubMed ID: 16471115
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
Dutta S; Zhang Y; Selness DS; Lee LL; Williams LA; Sommerville KW
Epilepsy Res; 2002 Mar; 49(1):1-10. PubMed ID: 11948003
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
32. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
33. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
34. Divalproex to divalproex extended release conversion.
Dutta S; Reed RC
Clin Drug Investig; 2004; 24(9):495-508. PubMed ID: 17523712
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
Klotz U
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
Dutta S; Reed RC; Cavanaugh JH
Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
[TBL] [Abstract][Full Text] [Related]
37. Rapid oral loading of extended release divalproex in patients with acute mania.
Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D
Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770
[TBL] [Abstract][Full Text] [Related]
38. Extended-release formulations for the treatment of epilepsy.
Bialer M
CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
[TBL] [Abstract][Full Text] [Related]
39. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
[TBL] [Abstract][Full Text] [Related]
40. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
